For laboratory research use only. This page summarises published scientific literature on PT-141 (Bremelanotide) in plain English, in a neutral research style. It is not medical advice and contains no guidance on doses, administration or human use.
PT-141 (Bremelanotide) UK: Complete Research Guide (2026)
Research Disclaimer: PT-141 (Bremelanotide) is sold for research and laboratory purposes only. It is not approved for human consumption and should not be used outside of controlled research settings. All information presented here is for educational purposes only.
What is PT-141 (Bremelanotide)?
PT-141, commonly known by its research designation bremelanotide, is a synthetic peptide that acts as a melanocortin receptor agonist. The compound was originally developed through research into melanocortin biology and has emerged as a significant research tool for studying the central nervous system regulation of sexual function and arousal. Unlike phosphodiesterase-5 inhibitors (PDE5i) such as sildenafil, which act peripherally on erectile tissue, PT-141 operates centrally through melanocortin receptors in the brain, making it a unique research compound for investigating the neurobiological basis of sexual motivation and function.
PT-141 is a seven-amino acid peptide derived from the alpha-melanocyte-stimulating hormone (α-MSH), a natural melanocortin hormone. The compound’s development was motivated by the serendipitous observation that subjects receiving a tanning peptide (Melanotan II) reported spontaneous episodes of sexual arousal, prompting research into melanocortin’s role in central sexual arousal mechanisms. PT-141 represents a refined, selective version of these early melanocortin compounds, optimised for research into sexual function whilst minimising off-target melanin production effects.
Mechanism of Action: Melanocortin Receptor Agonism
PT-141 exerts its biological effects through activation of melanocortin receptors, specifically the melanocortin 3 receptor (MC3R) and melanocortin 4 receptor (MC4R) in the central nervous system. These receptors are G-protein-coupled receptors (GPCRs) widely distributed throughout the hypothalamus and other brain regions involved in arousal, motivation, and sexual function.
The hypothalamus is a critical brain region regulating numerous physiological processes, including sexual behaviour and arousal. Research has identified melanocortin signalling as a key modulatory pathway in sexual motivation and erectile/clitoral vascular function. When PT-141 binds to MC3R and MC4R receptors, it activates intracellular signalling cascades that enhance dopaminergic and other neurotransmitter systems involved in sexual arousal and motivation.
A critical aspect of PT-141’s mechanism is that it operates centrally — in the brain — rather than peripherally on erectile tissue. This central mechanism of action is fundamentally different from PDE5 inhibitors, which enhance erectile function by increasing cyclic GMP in penile smooth muscle. PT-141 instead enhances the central arousal and motivation components of sexual function, working upstream of the peripheral vascular mechanisms that produce erection or vaginal vasocongestion.
The selectivity of PT-141 for MC3R and MC4R, relative to other melanocortin receptors (particularly MC1R, which mediates melanin production), is a key feature of the compound’s design. This selectivity reduces unwanted side effects related to increased skin pigmentation, which were prominent in earlier, less selective melanocortin agonists.
Sexual Dysfunction Research: Male and Female Studies
Research examining PT-141’s effects on sexual function has included studies in both male and female research subjects, with distinct clinical presentations of sexual dysfunction being investigated in each population.
Libido and Arousal Research
Beyond its direct effects on sexual function, research has examined PT-141’s effects on sexual motivation, libido, and subjective arousal responses. These investigations are particularly valuable because they address the central, motivational aspects of sexual function that extend beyond erectile or vascular mechanisms.
Additionally, research has noted that PT-141’s arousal-enhancing effects appear to be relatively context-dependent; that is, the compound enhances arousal in response to sexual stimuli but does not produce spontaneous, context-independent arousal in the manner of some other compounds. This context-dependence is thought to reflect the compound’s mechanism of enhancing sensitivity to sexual cues rather than inducing a non-specific excitatory state.
PT-141 vs PDE5 Inhibitors: Mechanistic Differences
The distinction between PT-141 and phosphodiesterase-5 (PDE5) inhibitors such as sildenafil (Viagra) represents a fundamental difference in research approaches to sexual dysfunction, reflecting different underlying physiological mechanisms.
PDE5 inhibitors (peripheral mechanism): PDE5 inhibitors work by inhibiting the phosphodiesterase-5 enzyme in penile vascular smooth muscle. This inhibition increases cyclic GMP (cGMP) concentrations, promoting smooth muscle relaxation, vasodilation, and increased blood flow to erectile tissue. Importantly, PDE5 inhibitors are primarily peripheral agents; they require sexual stimulation or sexual cues to produce their effects and primarily enhance the peripheral vascular mechanisms of erection. They do not significantly enhance central sexual motivation or desire.
PT-141 (central mechanism): PT-141 operates through central melanocortin receptors in the brain, enhancing the motivational and arousal components of sexual function. The compound affects central dopaminergic and other neurotransmitter systems that regulate sexual desire, motivation, and arousal perception. Additionally, PT-141 may have peripheral effects on vascular function through central-to-peripheral neural pathways, but its primary site of action is central.
Clinical and research implications: These mechanistic differences suggest that PT-141 and PDE5 inhibitors may be effective in different clinical contexts or may have complementary effects. PDE5 inhibitors are most effective for erectile dysfunction with adequate sexual stimulation present, whilst PT-141 may be particularly valuable for low sexual desire or arousal deficits where central neurobiological dysregulation is the primary issue. Research in subjects who are unresponsive to PDE5 inhibitors has suggested that PT-141 may be effective, supporting the concept of complementary mechanisms.
Additionally, PDE5 inhibitors require sexual stimulation to produce their full effects, whereas PT-141 appears capable of enhancing arousal with less dependence on external sexual stimuli, reflecting its direct effect on central arousal mechanisms.
PT-141 vs Melanotan 2: Structural and Functional Differences
PT-141 and Melanotan 2 (MT2) are both melanocortin receptor agonists but differ in their chemical structure, receptor selectivity profile, and consequent biological effects.
Structural differences: Melanotan 2 is a hexapeptide (six amino acids) with a relatively non-selective melanocortin receptor agonist profile, activating MC1R, MC3R, MC4R, and MC5R with varying affinities. PT-141, by contrast, is a seven-amino acid peptide with greater selectivity for MC3R and MC4R relative to MC1R, conferring reduced effects on melanin production.
Off-target effects — pigmentation: Because Melanotan 2 is a non-selective melanocortin agonist, it readily activates MC1R on melanocytes, promoting melanin synthesis and consequent darkening of skin pigmentation. This effect is a notable side effect of Melanotan 2 research and is unrelated to the sexual function effects. PT-141’s selectivity for MC3R/MC4R reduces its activity at MC1R, minimising unwanted skin pigmentation, making it a more selective research tool for investigating sexual function without the confounding melanin production effects.
Sexual function effects: Both compounds enhance sexual function through melanocortin receptor activation, but PT-141’s greater selectivity for MC3R/MC4R may result in a more pronounced effect on sexual arousal and motivation relative to other melanocortin effects. Research comparing the two compounds directly is limited, but the chemical selectivity suggests potential differences in potency or specificity for sexual function endpoints.
Research implications: For research specifically aimed at investigating sexual function and arousal, PT-141’s greater selectivity makes it the preferred compound, as it allows investigation of sexual effects without the complicating variable of increased skin pigmentation. The selectivity represents an advance in melanocortin research compounds.
UK Legal Status
PT-141 (Bremelanotide) is not approved as a pharmaceutical medication in the United Kingdom. It is classified as a research chemical and is legally available for purchase through licensed research suppliers for legitimate research and laboratory purposes only. The compound is not controlled under the Misuse of Drugs Act, though it is subject to regulations governing research chemicals and peptides.
All UK suppliers must ensure that PT-141 is sold with appropriate labelling indicating its research-only status and explicitly stating that it is not approved for human consumption. Researchers and institutions must purchase PT-141 through reputable, licensed suppliers and maintain proper documentation of its use for legitimate research purposes.
UK Sourcing and Quality Standards
When sourcing PT-141 in the United Kingdom, researchers should prioritise suppliers who maintain rigorous quality assurance and provide comprehensive documentation. Reputable UK suppliers provide certificates of analysis (COA) from independent third-party laboratories, confirming the purity, identity, and potency of supplied compounds.
Quality indicators to evaluate include: third-party laboratory verification of purity and amino acid sequence accuracy, clear documentation of manufacturer identity and GMP compliance, proper storage and handling procedures, and transparent, competitive pricing relative to quality provided. Establishing relationships with trusted UK suppliers ensures consistent product quality and regulatory compliance across research projects.
Limits of the evidence
Published findings come from specific study designs, often in cell systems or animals, and do not transfer automatically to other settings. A paper about a molecule is not proof that any particular batch has a given biological effect. Purity data show what is in a vial; they do not show sterility, safety or suitability for any use outside the laboratory.
Laboratory handling
- Store lyophilised powder sealed, cold (−20 °C for long-term storage), dry and protected from light.
- Let vials reach room temperature before opening to limit condensation.
- Prepare solutions with suitable laboratory solvents and calibrated equipment, and label each with lot number, concentration and date.
- Split solutions into single-use aliquots and avoid repeated freeze–thaw cycles.
- Use the peptide calculator for concentration arithmetic (mg/mL).
For laboratory research use only. PT-141 (Bremelanotide) sold by Peptides Lab UK is supplied strictly for in vitro laboratory research. It is not for human or veterinary use, and nothing on this page is medical advice or guidance on administration. UK purchasers are responsible for complying with all applicable legislation.
